ibrutinib,venetoclax
janssen,roche,Abbvie
['glow', 'leukemia', 'lymphoma', 'janssen']
for us #hcps attending #ash22 today, see dr. carsten u. niemann ( ) present residual disease kinetics among patients with first-line treatment of chronic lymphocytic #leukemia or small lymphocytic #lymphoma in the phase 3 glow study.
Dedicated to sharing Janssen Oncology scientific communications for US HCPs. Account run by Janssen Global Services LLC. Review our Guidelines: https://t.co/uieWByQjn3.